Lucia Romero
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Lucia Romero has a total of 83 co-authors. Here are the top co-authors by number of shared publications:
- Beatriz Trenor
Centro de Investigación e Innovación en Bioingeniería (CI2B), Universitat Politècnica de València, 46022 Valencia, Spain
21 shared publications - Javier Saiz
Centro de Investigación e Innovación en Bioingeniería (CI2B), Universitat Politècnica de València, 46022 Valencia, Spain
21 shared publications - Jose Maria Ferrero
Centro de Investigación e Innovación en Bioingeniería, Universitat Politècnica de València, Valencia, Spain
17 shared publications - Julio Gomis-Tena
Department of Electronic Engineering, Universitat Politcnica de Valncia, Valencia, Spain
5 shared publications - Fernando Escobar
Centro de Investigación e Innovación en Bioingeniería (Ci2B), Universitat Politècnica de València, Valencia, Spain
4 shared publications - Germán Moltó
Instituto de Instrumentación para Imagen Molecular (I3M) Centro Mixto CSIC -Universitat Politècnica de València Camino de Vera s/n 46022 Valencia Spain
4 shared publications
Latest Publications
- Open Access
- 31 October 2026
- Published by Elsevier in The Journal of Precision Medicine: Health and Disease
- Vol. 8
In silico trials under long QT syndrome conditions using static and dynamic formulations of drugs
- 31 October 2026
- Published by Elsevier in The Journal of Precision Medicine: Health and Disease
- Vol. 8
Open AccessIn silico trials under long QT syndrome conditions using static and dynamic formulations of drugs
- Open Access
Electrophysiological dependent antiarrhythmic drug response in population-based models of paroxysmal atrial fibrillation
Response to antiarrhythmic drugs varies markedly across patients with atrial fibrillation (AF), suggesting that treatment efficacy depends on the interaction between drug-specific mechanisms and patient-specific electrophysiological substrate. Here, we used population-based computational models to investigate how electrophysiological substrate and inter-individual ionic variability influence pharmacological efficacy and the underlying mechanisms. Two populations of human atrial models were generated from distinct substrates: a reference left atrial model and a second model incorporating inward-rectifier-enhancement (IRE) through a 2-fold increase in I K1 and I K,ACh . Both populations were independently calibrated against the same experimental datasets from patients with paroxysmal AF (pAF), yielding pAF and IRE-pAF populations. Sustained reentrant activity was induced in two-dimensional tissue simulations and subsequently used to assess cardioversion efficacy of flecainide, vernakalant and tertiapin-Q. Despite satisfying the same calibration criteria, IRE-pAF population exhibited a more arrhythmogenic phenotype: shorter refractoriness, higher dominant frequency (DF) and greater rotor stability. Antiarrhythmic efficacy markedly differed between substrates. Flecainide cardioversion decreased in IRE-pAF compared with pAF (34% vs 21%), whereas I K,ACh -targeting therapies preserved or improved efficacy in IRE-pAF (vernakalant: 41% vs 44%, tertiapin-Q: 11% vs 18%). Across drugs and substrates, rotor DF strongly influenced cardioversion outcome, with higher-frequency rotors showing lower termination rates. Drug-induced DF reduction emerged as a key mechanism associated with successful cardioversion, whereas effective refractory period (ERP) prolongation alone did not consistently explain treatment efficacy. In pAF, vernakalant achieved higher cardioversion efficacy than flecainide despite a smaller increase in ERP and greater DF reduction. Ionic analyses further showed that elevated I K,ACh favored responses to vernakalant and tertiapin-Q. These findings demonstrate that cardioversion efficacy emerges from the interaction between electrophysiological substrate, rotor dynamics and drug-specific mechanisms. In particular, substrates differing in inward rectifier activity exhibit distinct response patterns, while DF emerges as a robust marker of pharmacological susceptibility and a potential guide for drug-mediated AF termination. Author summary: Antiarrhythmic drugs are commonly used to restore normal rhythm in patients with paroxysmal atrial fibrillation (pAF), but their effectiveness varies substantially among individuals. The reasons underlying this variability remain incompletely understood, limiting our ability to select the most appropriate treatment for a given patient. In this study, we used populations of computational models of human atrial tissue to investigate how differences in the underlying electrophysiological substrate influence drug response and the underlying mechanisms. We generated two pAF-like populations differing in the level of inward rectifier activity. Then, we evaluated the effects of three antiarrhythmic drugs with distinct mechanisms of action. Our results show that, while some therapies became less effective in the inward-rectifier-enhanced substrate, others maintained or even improved their performance. We also found that rotor dominant frequency (DF) was closely linked to treatment success and that drugs producing greater DF reduction were more likely to terminate AF. These findings highlight the importance of considering substrate-specific electrophysiology when evaluating antiarrhythmic therapies and illustrate how computational modeling can help uncover mechanisms of drug response. More broadly, our results suggest that electrophysiological markers such as DF may help identify patients more likely to benefit from specific rhythm-control strategies, supporting future personalized approaches for AF treatment.
Open AccessElectrophysiological dependent antiarrhythmic drug response in population-based models of paroxysmal atrial fibrillation
Response to antiarrhythmic drugs varies markedly across patients with atrial fibrillation (AF), suggesting that treatment efficacy depends on the interaction between drug-specific mechanisms and patient-specific electrophysiological substrate. Here, we used population-based computational models to investigate how electrophysiological substrate and inter-individual ionic variability influence pharmacological efficacy and the underlying mechanisms. Two populations of human atrial models were generated from distinct substrates: a reference left atrial model and a second model incorporating inward-rectifier-enhancement (IRE) through a 2-fold increase in I K1 and I K,ACh . Both populations were independently calibrated against the same experimental datasets from patients with paroxysmal AF (pAF), yielding pAF and IRE-pAF populations. Sustained reentrant activity was induced in two-dimensional tissue simulations and subsequently used to assess cardioversion efficacy of flecainide, vernakalant and tertiapin-Q. Despite satisfying the same calibration criteria, IRE-pAF population exhibited a more arrhythmogenic phenotype: shorter refractoriness, higher dominant frequency (DF) and greater rotor stability. Antiarrhythmic efficacy markedly differed between substrates. Flecainide cardioversion decreased in IRE-pAF compared with pAF (34% vs 21%), whereas I K,ACh -targeting therapies preserved or improved efficacy in IRE-pAF (vernakalant: 41% vs 44%, tertiapin-Q: 11% vs 18%). Across drugs and substrates, rotor DF strongly influenced cardioversion outcome, with higher-frequency rotors showing lower termination rates. Drug-induced DF reduction emerged as a key mechanism associated with successful cardioversion, whereas effective refractory period (ERP) prolongation alone did not consistently explain treatment efficacy. In pAF, vernakalant achieved higher cardioversion efficacy than flecainide despite a smaller increase in ERP and greater DF reduction. Ionic analyses further showed that elevated I K,ACh favored responses to vernakalant and tertiapin-Q. These findings demonstrate that cardioversion efficacy emerges from the interaction between electrophysiological substrate, rotor dynamics and drug-specific mechanisms. In particular, substrates differing in inward rectifier activity exhibit distinct response patterns, while DF emerges as a robust marker of pharmacological susceptibility and a potential guide for drug-mediated AF termination. Author summary: Antiarrhythmic drugs are commonly used to restore normal rhythm in patients with paroxysmal atrial fibrillation (pAF), but their effectiveness varies substantially among individuals. The reasons underlying this variability remain incompletely understood, limiting our ability to select the most appropriate treatment for a given patient. In this study, we used populations of computational models of human atrial tissue to investigate how differences in the underlying electrophysiological substrate influence drug response and the underlying mechanisms. We generated two pAF-like populations differing in the level of inward rectifier activity. Then, we evaluated the effects of three antiarrhythmic drugs with distinct mechanisms of action. Our results show that, while some therapies became less effective in the inward-rectifier-enhanced substrate, others maintained or even improved their performance. We also found that rotor dominant frequency (DF) was closely linked to treatment success and that drugs producing greater DF reduction were more likely to terminate AF. These findings highlight the importance of considering substrate-specific electrophysiology when evaluating antiarrhythmic therapies and illustrate how computational modeling can help uncover mechanisms of drug response. More broadly, our results suggest that electrophysiological markers such as DF may help identify patients more likely to benefit from specific rhythm-control strategies, supporting future personalized approaches for AF treatment.
- Open Access
- 27 August 2026
- Published by Elsevier in SSRN Electronic Journal
Electro-anatomical Factors Contributing to Arrhythmia Recurrence as Atypical Flutter After PVI. Atrial Computer Model
Aims,After pulmonary vein isolation (PVI), 4-10% of patients show atypical flutter recurrence, most commonly, perimitral flutter (PMF). The factors that favor this phenomenon have not been fully described. This study evaluates different electro-anatomical factors and their impact in PMF recurrence after PVI using computer models.,Methods and results,Computational simulations were performed in three realistic bi-atrial models, with four different ablation patterns, which vary in the corridor size after PVI. Model characterization was performed using clinically acquired data from electro-anatomical maps. The Courtemanche et al. cellular model was adjusted to match clinically measured effective refractory period (ERP) values. An arrhythmogenic activity was induced and its temporal evolution was studied, classified as non-sustained arrhythmia, atrial fibrillation (AF) or PMF. The influence of several electro-anatomical factors on arrhythmic activity evolution was studied, such as conduction velocity (CV), posterior wall corridor size, left atrium volume, ERP, anisotropy, and the reconnection of a lateral mitral isthmus ablation line. Greater PMF organization was observed in models with slower CV, larger volumes, and narrower conduction gaps in the mitral ablation line. Statistically significant differences were observed for posterior wall narrowing (P<0.01), prolonged ERP (P<0.01), and increased anisotropy ratios (P=0.02), all of which were associated with higher PMF organization.,Conclusion,Electro-anatomical measures in patients with PMF showed a reduced CV around the perimitral region. Simulation analyses suggested that this slower conduction may facilitate PMF stabilization. PMF recurrence appeared to be influenced by multiple factors, including ERP, anisotropy, and conduction gaps along prior ablation lines.
- 27 August 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessElectro-anatomical Factors Contributing to Arrhythmia Recurrence as Atypical Flutter After PVI. Atrial Computer Model
Aims,After pulmonary vein isolation (PVI), 4-10% of patients show atypical flutter recurrence, most commonly, perimitral flutter (PMF). The factors that favor this phenomenon have not been fully described. This study evaluates different electro-anatomical factors and their impact in PMF recurrence after PVI using computer models.,Methods and results,Computational simulations were performed in three realistic bi-atrial models, with four different ablation patterns, which vary in the corridor size after PVI. Model characterization was performed using clinically acquired data from electro-anatomical maps. The Courtemanche et al. cellular model was adjusted to match clinically measured effective refractory period (ERP) values. An arrhythmogenic activity was induced and its temporal evolution was studied, classified as non-sustained arrhythmia, atrial fibrillation (AF) or PMF. The influence of several electro-anatomical factors on arrhythmic activity evolution was studied, such as conduction velocity (CV), posterior wall corridor size, left atrium volume, ERP, anisotropy, and the reconnection of a lateral mitral isthmus ablation line. Greater PMF organization was observed in models with slower CV, larger volumes, and narrower conduction gaps in the mitral ablation line. Statistically significant differences were observed for posterior wall narrowing (P<0.01), prolonged ERP (P<0.01), and increased anisotropy ratios (P=0.02), all of which were associated with higher PMF organization.,Conclusion,Electro-anatomical measures in patients with PMF showed a reduced CV around the perimitral region. Simulation analyses suggested that this slower conduction may facilitate PMF stabilization. PMF recurrence appeared to be influenced by multiple factors, including ERP, anisotropy, and conduction gaps along prior ablation lines.
- 17 July 2025
- Published by Universitat Politecnica de Valencia
Adquisición de competencias transversales UPV mediante una metodología basada en proyectos en la asignatura Computational Modeling and Simulation of Bioelectric Systems
Se sabe que la metodología de enseñanza-aprendizaje basada en proyectos favorece implicación del estudiantado. Por lo tanto, puede resultar interesante aprovechar este tipo de metodología para favorecer la adquisición de las competencias transversales. El objetivo de este trabajo consiste en diseñar, aplicar y valorar una innovación docente para que el estudiantado de las asignaturas Modeling and Simulation of Bioelectric Systems y Computational Modeling and Simulation of Bioelectric Systems del Máster Universitario de Ingeniería Biomédica, adquieran las competencias transversales UPV correspondientes con un nivel de dominio elevado empleando la metodología de aprendizaje basado en proyectos. Esta metodología se ha aplicado durante los cursos 2023-24 y 2024-25 y las competencias transversales trabajadas son “Compromiso social y medioambiental (CT1)”, “Innovación y creatividad (CT2)”, “Trabajo en equipo y liderazgo (CT3)”, “Comunicación efectiva (CT4)” y “Responsabilidad y toma de decisiones (CT5)”. La adquisición de estas competencias ha sido muy satisfactoria y la valoración del alumnado también. Además, metodología implantada es sostenible y puede llevarse a cabo los próximos cursos.
- 17 July 2025
- Published by Universitat Politecnica de Valencia
Adquisición de competencias transversales UPV mediante una metodología basada en proyectos en la asignatura Computational Modeling and Simulation of Bioelectric Systems
Se sabe que la metodología de enseñanza-aprendizaje basada en proyectos favorece implicación del estudiantado. Por lo tanto, puede resultar interesante aprovechar este tipo de metodología para favorecer la adquisición de las competencias transversales. El objetivo de este trabajo consiste en diseñar, aplicar y valorar una innovación docente para que el estudiantado de las asignaturas Modeling and Simulation of Bioelectric Systems y Computational Modeling and Simulation of Bioelectric Systems del Máster Universitario de Ingeniería Biomédica, adquieran las competencias transversales UPV correspondientes con un nivel de dominio elevado empleando la metodología de aprendizaje basado en proyectos. Esta metodología se ha aplicado durante los cursos 2023-24 y 2024-25 y las competencias transversales trabajadas son “Compromiso social y medioambiental (CT1)”, “Innovación y creatividad (CT2)”, “Trabajo en equipo y liderazgo (CT3)”, “Comunicación efectiva (CT4)” y “Responsabilidad y toma de decisiones (CT5)”. La adquisición de estas competencias ha sido muy satisfactoria y la valoración del alumnado también. Además, metodología implantada es sostenible y puede llevarse a cabo los próximos cursos.
- Open Access
- 18 December 2024
- Published by Elsevier in Computer Methods and Programs in Biomedicine
- Vol. 260, 108566
A simulation study of the impact of drug-IKr binding mechanisms on biomarkers of proarrhythmic risk reveals a crucial role in reverse use-dependence of action potential duration and a marked influence on the vulnerable window
- 18 December 2024
- Published by Elsevier in Computer Methods and Programs in Biomedicine
- Vol. 260, 108566
Open AccessA simulation study of the impact of drug-IKr binding mechanisms on biomarkers of proarrhythmic risk reveals a crucial role in reverse use-dependence of action potential duration and a marked influence on the vulnerable window
- Open Access
- 22 June 2024
- Published by Elsevier in Computer Methods and Programs in Biomedicine
- Vol. 254, 108293
Experimentally validated modeling of dynamic drug-hERG channel interactions reproducing the binding mechanisms and its importance in action potential duration.
- 22 June 2024
- Published by Elsevier in Computer Methods and Programs in Biomedicine
- Vol. 254, 108293
Open AccessExperimentally validated modeling of dynamic drug-hERG channel interactions reproducing the binding mechanisms and its importance in action potential duration.
- Open Access
- 11 October 2023
- Published by Elsevier in Computer Methods and Programs in Biomedicine
- Vol. 242, 107860
Combining pharmacokinetic and electrophysiological models for early prediction of drug-induced arrhythmogenicity
- 11 October 2023
- Published by Elsevier in Computer Methods and Programs in Biomedicine
- Vol. 242, 107860
Open AccessCombining pharmacokinetic and electrophysiological models for early prediction of drug-induced arrhythmogenicity
- Open Access
- 21 September 2022
- Published by Elsevier in Computer Methods and Programs in Biomedicine
- Vol. 226, 107148
Automatic modeling of dynamic drug-hERG channel interactions using three voltage protocols and machine learning techniques: A simulation study
- 21 September 2022
- Published by Elsevier in Computer Methods and Programs in Biomedicine
- Vol. 226, 107148
Open AccessAutomatic modeling of dynamic drug-hERG channel interactions using three voltage protocols and machine learning techniques: A simulation study
- Open Access
- 17 December 2020
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 11
Ranolazine as an Alternative Therapy to Flecainide for SCN5A V411M Long QT Syndrome Type 3 Patients
The prolongation of the QT interval represents the main feature of the long QT syndrome (LQTS), a life-threatening genetic disease. The heterozygous SCN5A V411M mutation of the human sodium channel leads to a LQTS type 3 with severe proarrhythmic effects due to an increase in the late component of the sodium current (INaL). The two sodium blockers flecainide and ranolazine are equally recommended by the current 2015 ESC guidelines to treat patients with LQTS type 3 and persistently prolonged QT intervals. However, awareness of pro-arrhythmic effects of flecainide in LQTS type 3 patients arose upon the study of the SCN5A E1784K mutation. Regarding SCN5A V411M individuals, flecainide showed good results albeit in a reduced number of patients and no evidence supporting the use of ranolazine has ever been released. Therefore, we ought to compare the effect of ranolazine and flecainide in a SCN5A V411M model using an in-silico modeling and simulation approach. We collected clinical data of four patients. Then, we fitted four Markovian models of the human sodium current (INa) to experimental and clinical data. Two of them correspond to the wild type and the heterozygous SCN5A V411M scenarios, and the other two mimic the effects of flecainide and ranolazine on INa. Next, we inserted them into three isolated cell action potential (AP) models for endocardial, midmyocardial and epicardial cells and in a one-dimensional tissue model. The SCN5A V411M mutation produced a 15.9% APD90 prolongation in the isolated endocardial cell model, which corresponded to a 14.3% of the QT interval prolongation in a one-dimensional strand model, in keeping with clinical observations. Although with different underlying mechanisms, flecainide and ranolazine partially countered this prolongation at the isolated endocardial model by reducing the APD90 by 8.7 and 4.3%, and the QT interval by 7.2 and 3.2%, respectively. While flecainide specifically targeted the mutation-induced increase in peak INaL, ranolazine reduced it during the entire AP. Our simulations also suggest that ranolazine could prevent early afterdepolarizations triggered by the SCN5A V411M mutation during bradycardia, as flecainide. We conclude that ranolazine could be used to treat SCN5A V411M patients, specifically when flecainide is contraindicated.
- 17 December 2020
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 11
Open AccessRanolazine as an Alternative Therapy to Flecainide for SCN5A V411M Long QT Syndrome Type 3 Patients
The prolongation of the QT interval represents the main feature of the long QT syndrome (LQTS), a life-threatening genetic disease. The heterozygous SCN5A V411M mutation of the human sodium channel leads to a LQTS type 3 with severe proarrhythmic effects due to an increase in the late component of the sodium current (INaL). The two sodium blockers flecainide and ranolazine are equally recommended by the current 2015 ESC guidelines to treat patients with LQTS type 3 and persistently prolonged QT intervals. However, awareness of pro-arrhythmic effects of flecainide in LQTS type 3 patients arose upon the study of the SCN5A E1784K mutation. Regarding SCN5A V411M individuals, flecainide showed good results albeit in a reduced number of patients and no evidence supporting the use of ranolazine has ever been released. Therefore, we ought to compare the effect of ranolazine and flecainide in a SCN5A V411M model using an in-silico modeling and simulation approach. We collected clinical data of four patients. Then, we fitted four Markovian models of the human sodium current (INa) to experimental and clinical data. Two of them correspond to the wild type and the heterozygous SCN5A V411M scenarios, and the other two mimic the effects of flecainide and ranolazine on INa. Next, we inserted them into three isolated cell action potential (AP) models for endocardial, midmyocardial and epicardial cells and in a one-dimensional tissue model. The SCN5A V411M mutation produced a 15.9% APD90 prolongation in the isolated endocardial cell model, which corresponded to a 14.3% of the QT interval prolongation in a one-dimensional strand model, in keeping with clinical observations. Although with different underlying mechanisms, flecainide and ranolazine partially countered this prolongation at the isolated endocardial model by reducing the APD90 by 8.7 and 4.3%, and the QT interval by 7.2 and 3.2%, respectively. While flecainide specifically targeted the mutation-induced increase in peak INaL, ranolazine reduced it during the entire AP. Our simulations also suggest that ranolazine could prevent early afterdepolarizations triggered by the SCN5A V411M mutation during bradycardia, as flecainide. We conclude that ranolazine could be used to treat SCN5A V411M patients, specifically when flecainide is contraindicated.
- 27 February 2020
- Published by American Chemical Society (ACS) in Journal of Chemical Information and Modeling
- Vol. 60 (3) , 1779-1790
When Does the IC50 Accurately Assess the Blocking Potency of a Drug?
Preclinical assessment of drug-induced proarrhythmicity is typically evaluated by the potency of the drug to block the potassium human ether-à-go-go-related gene (hERG) channels, which is currently quantified by the IC50. However, it depends on the experimental conditions. Our aim is to improve the evaluation of the blocking potency of drugs by designing experimental stimulation protocols to measure the IC50 that will help to decide whether the IC50 is representative enough. We used the state-of-the-art mathematical models of the cardiac electrophysiological activity to design three stimulation protocols that enhance the differences in the probabilities to occupy a certain conformational state of the channel and, therefore, the potential differences in the blocking effects of a compound. We simulated an extensive set of 144 in silico IKr blockers with different kinetics and affinities to conformational states of the channel and we also experimentally validated our key predictions. Our results show that the IC50 protocol dependency relied on the tested compound. Some of them showed no differences or small differences on the IC50 value, which suggests that the IC50 could be a good indicator of the blocking potency in these cases. However, others provided highly protocol dependent IC50 values, which could differ even two orders of magnitude. Moreover, the protocols yielding the maximum IC50 and minimum IC50 depended on the drug, which complicates the definition of a “standard” protocol to minimize the influence of the stimulation protocol on the IC50 measurement in safety pharmacology. As a conclusion, we propose the adoption of our three-protocol IC50 assay to estimate the potency to block hERG in vitro. If the IC50 values obtained for a compound are similar, then the IC50 could be used as an indicator of its blocking potency, otherwise kinetics and state-dependent binding properties should be accounted.
- 27 February 2020
- Published by American Chemical Society (ACS) in Journal of Chemical Information and Modeling
- Vol. 60 (3) , 1779-1790
When Does the IC50 Accurately Assess the Blocking Potency of a Drug?
Preclinical assessment of drug-induced proarrhythmicity is typically evaluated by the potency of the drug to block the potassium human ether-à-go-go-related gene (hERG) channels, which is currently quantified by the IC50. However, it depends on the experimental conditions. Our aim is to improve the evaluation of the blocking potency of drugs by designing experimental stimulation protocols to measure the IC50 that will help to decide whether the IC50 is representative enough. We used the state-of-the-art mathematical models of the cardiac electrophysiological activity to design three stimulation protocols that enhance the differences in the probabilities to occupy a certain conformational state of the channel and, therefore, the potential differences in the blocking effects of a compound. We simulated an extensive set of 144 in silico IKr blockers with different kinetics and affinities to conformational states of the channel and we also experimentally validated our key predictions. Our results show that the IC50 protocol dependency relied on the tested compound. Some of them showed no differences or small differences on the IC50 value, which suggests that the IC50 could be a good indicator of the blocking potency in these cases. However, others provided highly protocol dependent IC50 values, which could differ even two orders of magnitude. Moreover, the protocols yielding the maximum IC50 and minimum IC50 depended on the drug, which complicates the definition of a “standard” protocol to minimize the influence of the stimulation protocol on the IC50 measurement in safety pharmacology. As a conclusion, we propose the adoption of our three-protocol IC50 assay to estimate the potency to block hERG in vitro. If the IC50 values obtained for a compound are similar, then the IC50 could be used as an indicator of its blocking potency, otherwise kinetics and state-dependent binding properties should be accounted.